Max Healthcare Institute Ltd.
Pharma · NSE
52-week range
₹903 – ₹1,314
From 52w high
-23.0%
RSI (14)
55.6
vs SMA 50 / 200
↑ 50 · ↓ 200
Max Healthcare Institute (MAXHEALTH) trades at ₹1,012.50, approximately 7.8% below its 200-day SMA of ₹1,097.48, and is down 12.31% over the past 12 months against a 52-week drawdown of 22.96%. The company has delivered 26.6% earnings CAGR over 5 years with positive free cash flow in 4 of the available years, while carrying a rising debt load with D/E of 32.58. At a trailing PE of 69.47 and quality score of 54 — highest among its 6-stock peer set — the stock is priced at a sector premium despite recent price weakness.
- ✓Earnings CAGR of 26.6% over 5 years is the clearest fundamental driver, supported by a 5-year revenue growth rate of 10.7%, indicating profitable scaling of the hospital network.
- ✓Free cash flow has been positive in 4 of the tracked years, suggesting the business generates cash despite its capital-intensive model.
- ✓Quality score of 54 ranks first among the 6-stock peer group, which includes Apollo Hospitals (42), Sun Pharma (50), Divi's Labs (34), Dr. Reddy's (32), and Cipla (30).
- ✓Forward PE of 48.60 represents a compression from the trailing PE of 69.47, implying that consensus earnings estimates project meaningful profit growth in the near term.
- ✗Price has declined 12.31% over 12 months and remained below the 200-day SMA (₹1,097.48) while the 50-day SMA (₹1,003.68) is below the 200-day — a configuration consistent with a medium-term downtrend.
- ✗Debt-to-equity of 32.58 is elevated and trending upward, increasing sensitivity to interest-rate movements and refinancing risk in a sector where capital expenditure is structurally high.
- ✗ROE above 15% has been recorded in zero years within the persistence window; without this metric, the quality score's composition rests primarily on earnings and FCF consistency rather than return on capital.
- ✗Trailing PE of 69.47 is the second-highest in the peer group; at this multiple, even modest earnings misses could drive meaningful multiple compression.
- ·Q4 2026 results coverage appeared in Mint on 8 May 2026; the article was classified as neutral in tone, providing no directional signal on the earnings outcome.
- ·A postal ballot notice for director re-appointment was filed in April 2026, a routine governance event with no immediate financial implications noted in coverage.
- ·With only 2 news items captured in the analysis window, the news environment for MAXHEALTH is sparse and no significant corporate events or regulatory developments were identified beyond the results release.
- ?How does Max Healthcare's debt-to-equity trajectory compare to its hospital-sector peers (e.g., Apollo Hospitals) over the same 5-year window, and at what D/E level has the sector historically seen credit stress?
- ?Does the 26.6% earnings CAGR reflect organic bed additions and occupancy improvements, or is it driven by acquisitions — and how does that distinction affect the sustainability of the growth rate?
- ?The forward PE of 48.60 implies a specific earnings growth forecast; if actual earnings come in below that consensus, how sensitive is the valuation to a 10–20% earnings revision?
- ?The stock has underperformed its own 200-day SMA for an extended period while fundamentals appear to be improving — what has historically resolved similar divergences for capital-intensive healthcare businesses in India?
PE
69.5
Forward PE
48.6
ROE
—
Profit margin
+17.4%
D/E
32.58
Dividend yield
+0.1%
Quality score
54/100
ROE 5y above 15%
0/5 yrs
FCF 5y positive
4/5 yrs
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 10 May 2026.